ElectroCore: a Finalist in the 2015 FT ArcelorMittal Boldness in Business Awards Technology Category

Basking Ridge, NJ, April 01, 2015 --(PR.com)-- At the annual FT ArcelorMittal Boldness in Business awards held in London last week electroCore was one of six finalists in the ‘Technology’ category, in a competition that included over 250 companies, which Open Garden won for its FireChat digital app(1).

ElectroCore, a world leader in electroceuticals was nominated for its pioneering development of gammaCore, the non-invasive delivery of vagus nerve stimulation, which has proven to be effective in the treatment and prevention of severe primary headaches – cluster and migraine.

The gammaCore treatment, which patients can self-administered in 2-minute doses in the privacy of their homes, involves placing the compact, hand-held gammaCore delivery device on the skin of the neck over the vagus nerve (at the point where the pulse is felt). Patients typically deliver one to three doses of the painless stimulation twice per day - morning and evening – to prevent the occurrence of headaches, and can be used acutely for the remaining breakthrough headaches that may occur.

Frank Amato COO of electroCore who attended the event commented: “We were honored to be a finalist in such a prestigious competition, and particularly to have been nominated in the technology sector, which featured many amazing innovations across the full spectrum of science and engineering. We believe that stimulating the nervous system to alter the biochemistry of the brain is the future of medicine for many indications, and will, because of its safety, tolerability, cost effectiveness, and ease of use, soon represent the norm for resolving many medical conditions. What our company has done is to take the proven treatment that is vagus nerve stimulation, and extract its therapeutic value from its prior delivery device, which was an expensive, surgically implanted device, and replaced it with a compact, inexpensive hand-held device which a patient can use wherever he or she may be.”

GammaCore has already received regulatory approval for the acute and/or preventative treatment of cluster headache, migraine and medication overuse headache in the EU, South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for the prevention and the acute treatment of cluster headache and treatment of migraine. In the US, FDA approval is anticipated shortly.

(1) The FT Boldness in Business Award Categories comprise: Drivers of Change; Technology; Corporate Responsibility/Environment; Smaller Company; Developing Markets; Entrepreneurship and Person of the Year.

About electroCore
ElectroCore, which is based in New Jersey, is focused on developing non-invasive Vagus Nerve Stimulation (nVNS) self-administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.

Since its founding, electroCore, has raised more than $80 million from investors including Merck's Global Healthcare Innovation fund, and the venture funds of Easton Capital and Core Ventures.